ATI RN
ATI Pharmacology Proctored Exam 2019
1. A healthcare professional is preparing to administer dextrose 5% in water (D5W) 750 mL IV to infuse over 6 hr. How many mL/hr should the IV pump be set to deliver?
- A. 125 mL/hr
- B. 100 mL/hr
- C. 150 mL/hr
- D. 200 mL/hr
Correct answer: A
Rationale: To calculate the flow rate, divide the total volume by the total time: 750 mL / 6 hr = 125 mL/hr. Therefore, the IV pump should be set to deliver 125 mL/hr to infuse D5W 750 mL over 6 hours. Choice B (100 mL/hr) is incorrect because it does not accurately divide the total volume by the total time. Choice C (150 mL/hr) and Choice D (200 mL/hr) are incorrect as they are not the correct flow rates needed to infuse the D5W solution over the specified time period.
2. A healthcare provider is teaching a client who has a new prescription for Bisacodyl suppositories. Which of the following information should the provider include?
- A. Expect results within 15 to 60 minutes.
- B. Insert the suppository as directed by the healthcare provider.
- C. Keep the suppository at room temperature.
- D. Expect rectal burning.
Correct answer: D
Rationale: When educating a client about Bisacodyl suppositories, it is important to include information about the common side effects. Rectal burning is a frequent side effect that can occur after using Bisacodyl suppositories, so the client should be informed to expect this discomfort. The onset of action for Bisacodyl suppositories is typically within 15 to 60 minutes, so the client should expect results relatively quickly, not in 6 to 12 hours. It is essential to follow the healthcare provider's instructions on how to insert the suppository correctly. Keeping the suppository at room temperature is sufficient; refrigeration is not required. Therefore, option D is the correct choice as it addresses a common side effect and prepares the client for potential discomfort. Options A, B, and C are incorrect as they do not focus on a significant side effect, proper administration, or storage requirements.
3. A healthcare provider is reviewing a client's health record and notes that the client is experiencing episodes of hypokalemia. Which of the following medications should the healthcare provider identify as a cause of the client's hypokalemia?
- A. Captopril
- B. Lisinopril
- C. Furosemide
- D. Spironolactone
Correct answer: C
Rationale: Furosemide is a loop diuretic that acts on the kidneys to increase urine production. This increased urine output can lead to the excessive excretion of potassium, resulting in hypokalemia. Monitoring potassium levels and considering supplementation may be necessary when a patient is on furosemide to prevent or manage hypokalemia.
4. When providing teaching to a client starting therapy with trastuzumab, which finding should the nurse instruct the client to report?
- A. Dyspnea
- B. Constipation
- C. Tinnitus
- D. Dry mouth
Correct answer: A
Rationale: The correct answer is A: Dyspnea. The nurse should instruct the client to report dyspnea because it can indicate pulmonary toxicity, a serious adverse effect of trastuzumab. Monitoring and early reporting of respiratory symptoms like dyspnea are essential to prevent further complications and ensure timely intervention. Choices B, C, and D are incorrect because constipation, tinnitus, and dry mouth are not typically associated with trastuzumab therapy and are not priority symptoms that require immediate reporting for this specific medication.
5. A client has been prescribed Valsartan. Which of the following adverse effects should the nurse monitor?
- A. Hyperkalemia
- B. Hypoglycemia
- C. Bradycardia
- D. Hypercalcemia
Correct answer: A
Rationale: Corrected Rationale: Valsartan is an angiotensin II receptor blocker (ARB) that can lead to hyperkalemia by inhibiting the action of aldosterone. Hyperkalemia is a potential adverse effect, making it essential for the nurse to closely monitor the client's potassium levels to prevent complications such as cardiac arrhythmias. Incorrect Options Rationale: - Option B, Hypoglycemia, is not a common adverse effect of Valsartan. - Option C, Bradycardia, is not typically associated with Valsartan use. - Option D, Hypercalcemia, is not a known adverse effect of Valsartan; instead, Valsartan can lead to hyperkalemia.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access